China approves three Gilead remdesivir patents for COVID-19 treatment

US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration (CNIPA).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

China unveils new drug patenting rules

11 February 2021 China has introduced new measures to enforce a patent linkage system and proposed draft rules on how a patent owner can challenge the approval of a drug.

Big Pharma

Novavax partners with Takeda to deliver COVID-19 vaccine in Japan

10 August 2020 US biotechnology company Novavax has signed a deal with Takeda Pharmaceuticals to develop, manufacture and market a COVID-19 vaccine in Japan, it was announced on Friday, August 7.

Asia

Rouse and Codex launch new China partnership

4 June 2020 IP firm Rouse will collaborate with life sciences service provider Codex to support companies looking to enter the Chinese market.